Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

QNCX stock hub

Quince Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

QNCXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

20.9M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

QNCX

In the news

Latest news · QNCX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-227.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All QNCX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

174

Groups with data

Currency

USD

Showing 174 of 174 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001145404
Company name	Quince Therapeutics, Inc.
Country	United States
Country code	US
Cusip	22053A206
Employees	38
Employees Change	2%
Employees Change Percent	5.56
Enterprise value	$21.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2019-05-09
Isin	US22053A2069
Last refreshed	2026-05-10
Market cap	$20.9M
Market cap category	Nano-Cap
Price	$1.28
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	QNCX
Website	https://www.quincetx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-402.49%
FCF yield	-200.23%

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-84M
Net Income Growth Years	0%
Profit Per Employee	$-2.2M
ROA	-30.31
Roa5y	-23.81
ROCE	-100.3
ROIC	-227.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-87.71%
Cagr3y	-56.63%
Cagr5y	-67.83%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$93.5M
Cash	$17.8M
Current Assets	$22.9M
Current Liabilities	$43.2M
Debt	$18.5M
Equity	$-35.7M
Interest Coverage	-55.17
Liabilities	$129.2M
Long Term Assets	$70.6M
Long Term Liabilities	$86M
Net Cash	$-719,000
Net Cash By Market Cap	$-3.45
Tangible Book Value	$-103.5M
Tangible Book Value Per Share	$-18.58
WACC	8.33

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.53
Net Working Capital	$-19.9M
Quick ratio	0.49
Working Capital	$-20.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-15.8%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-87.69%
200-day SMA	15.23
3Y total return	-91.85%
50-day SMA	1.16
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.65%
All Time High	1,219.8
All Time High Change	-99.9%
All Time High Date	2021-08-10
All Time Low	0.8
All Time Low Change	60%
All Time Low Date	2026-03-20
ATR	0.22
Beta	1.45
Beta1y	1.08
Beta2y	0.34
Ch YTD	-96.18
High	1.32
High52	45.5
High52 Date	2025-12-12
High52ch	-97.19%
Low	1.2
Low52	0.8
Low52 Date	2026-03-20
Low52ch	60%
Ma50ch	10.25%
Premarket Change Percent	-1.54
Premarket Price	$1.28
Premarket Volume	25,850
Price vs 200-day SMA	-91.59%
RSI	44.04
RSI Monthly	38.84
RSI Weekly	34.11
Sharpe ratio	0.66x
Sortino ratio	1.75
Total Return	-15.8%
Tr YTD	-96.18
Tr1m	-21.47%
Tr1w	-3.76%
Tr3m	-7.98%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	1
Analyst Ratings	Hold
Analyst Ratings Top	Hold
Earnings EPS Estimate	$-1.87
Operating Income	$-50.4M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	15,708,651%
Float Percent	96.37%
Shares Insiders	3.63%
Shares Institutions	16.28%
Shares Out	16,300,740
Shares Qo Q	3.21%
Shares Yo Y	15.8%
Short Float	12.43%
Short Ratio	0.17
Short Shares	11.97

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-46.9M
Average Volume	1,698,654.95x
Bv Per Share	-6.41
CAPEX	$-352,000
Ch1m	-21.47
Ch1w	-3.76
Ch1y	-87.69
Ch3m	-7.98
Ch3y	-91.85
Ch5y	-99.65
Ch6m	-91.79
Change	-1.54%
Change From Open	0
Close	1.3
Days Gap	-1.54
Depreciation Amortization	142,000
Dollar Volume	1,595,761.9
Earnings Date	2026-05-22
Earnings Time	bmo
EBIT	$-50.4M
EBITDA	$-50.3M
EPS	$-16.76
F Score	1
FCF	$-41.8M
FCF EV Yield	-193.56x
FCF Per Share	$-2.56
Financing CF	17,909,000
Fiscal Year End	December
Founded	2,012
Income Tax	$3.2M
Investing CF	23,227,000
Ipr	-92.47
Iprfo	-99.36
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-10
Last Report Date	2025-12-31
Last Split Date	2026-04-13
Last Split Type	Reverse
Ma150	14.83
Ma150ch	-91.37%
Ma20	1.3
Ma20ch	-1.31%
Net CF	-403,000
Next Earnings Date	2026-05-22
Open	1.28
Optionable	Yes
Position In Range	65.04
Post Close	1.28
Postmarket Change Percent	0.58
Postmarket Price	$1.29
Ppne	1,048,000
Pre Close	1.3
Price Date	2026-05-08
Relative Volume	0.73x
Share Based Comp	5,105,000
Tr6m	-91.79%
Us State	California
Volume	1,246,689

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does QNCX pay a dividend?

Capital-return profile for this ticker.

Performance

QNCX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns QNCX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+16.3%

Float: +96.4% of shares outstanding

Insider ownership

+3.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

QNCX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.0

Neutral momentum band

Price vs 200-day MA

-91.6%

50/200-day relationship not available

Beta (5Y)

1.45

More volatile than the market

Sharpe ratio

0.66

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About QNCX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current QNCX stock rating?

Quince Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full QNCX analysis?

The full report lives at /stocks/QNCX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for QNCX?

The latest report frames QNCX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the QNCX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.